---
document_datetime: 2023-10-31 11:12:58
document_pages: 12
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/docetaxel-kabi-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
document_name: docetaxel-kabi-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
version: success
processing_time: 6.4926594
conversion_datetime: 2025-12-28 03:57:17.972412
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Docetaxel Kabi

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0038              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 26/09/2023                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IA/0037   | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                          | 02/06/2023   | n/a        |                       |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|
| IA/0036   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 21/03/2023   | n/a        |                       |
| IA/0035   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer      | 11/01/2022   | n/a        |                       |
| IB/0034   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                       | 17/09/2021   | n/a        |                       |
| IB/0033   | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                       | 26/02/2021   | n/a        |                       |
| IA/0032   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer      | 14/01/2021   | n/a        |                       |
| IB/0031/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites C.I.2.a - Change in the SPC, Labelling or PL of a                               | 12/10/2020   | 04/10/2021 | SmPC, Annex II and PL |

<div style=\"page-break-after: always\"></div>

|         | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |             |             |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------|
| IA/0030 | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of parameter)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 28/08/2020 | n/a        |             | an obsolete |
| IB/0029 | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 03/04/2020 | n/a        |             |             |
| IB/0028 | Update of sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC to include the treatment of patients with metastatic hormone-sensitive prostate cancer in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone. The Package Leaflet is updated accordingly. The changes have been implemented in line with the reference medicinal product. Additionally, MAH took the opportunity to correct minor editorial changes in SL, SK and RO Product Information. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO | 31/01/2020 | 24/02/2020 | SmPC and PL |             |

<div style=\"page-break-after: always\"></div>

|           | additional data is required to be submitted by MAH                                                                                                                                                                                                                                                                                                                                                                         |            |            |                        | new the         |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------|
| IAIN/0027 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                         | 11/12/2019 | n/a        |                        |                 |
| II/0022   | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                                                                                                                                                                                        | 25/07/2019 | n/a        |                        |                 |
| IB/0026/G | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate approved manufacturer | 11/07/2019 | n/a        |                        | from an already |
| IB/0025   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                               | 23/05/2019 | 28/06/2019 | SmPC, Labelling and PL |                 |
| IA/0024/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                         | 11/04/2019 | n/a        |                        |                 |

<div style=\"page-break-after: always\"></div>

|           | Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place   |            |            |                 | B.II.b.2.a -   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|----------------|
| IAIN/0023 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                | 21/03/2019 | 28/06/2019 | Annex II and PL |                |
| IB/0021   | B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation                                                                                                                                                                                                                                                                                                                                                                                                       | 04/01/2019 | n/a        |                 |                |
| IB/0020   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                          | 02/07/2018 | 28/06/2019 | SmPC and PL     |                |
| T/0019    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 18/04/2018 | 08/05/2018 | SmPC,           |                |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            | Labelling and PL   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|
| IB/0018/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 18/01/2018 | 08/05/2018 | SmPC and PL        |
| IA/0017/G | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 27/10/2017 | n/a        |                    |

<div style=\"page-break-after: always\"></div>

|         | relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                      |            |            |                                  |                                                                                                                                                                                                                                                                                                                                |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0016 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 01/08/2017 | 08/05/2018 | SmPC and PL                      |                                                                                                                                                                                                                                                                                                                                |
| R/0015  | Renewal of the marketing authorisation.                                                                                                                                                                                                                      | 15/12/2016 | 23/02/2017 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Docetaxel Kabi in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. Risk Management Plan (Version 1.0) is introduced. |
| IB/0014 | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                         | 12/07/2016 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                |
| IB/0013 | B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer                                                                      | 01/06/2016 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                |
| IB/0012 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 15/12/2015 | 12/12/2016 | SmPC and PL                      |                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| IAIN/0011          | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                | 16/07/2015   | n/a        |      |                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|-----------------------------------|
| IA/0010/G          | This was an application for a group of variations. B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits | 16/07/2015   | n/a        |      |                                   |
| PSUSA/1152/ 201311 | Periodic Safety Update EU Single assessment - docetaxel                                                                                                                                                                                                                                                                        | 25/09/2014   | n/a        |      | PRAC Recommendation - maintenance |
| IB/0009            | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                   | 17/07/2014   | 03/07/2015 | SmPC |                                   |
| IB/0007            | Update of section 4.4 and 4.5 of the SmPC in order to add a warning and update the safety information on interactions with CYP3A4 inhibitors further to the PRAC assessment of a signal. In addition, some inconsistencies have been rectified on the number and grade of alopecia adverse reactions in section                | 19/03/2014   | 22/05/2014 | SmPC |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | 4.8 of the SmPC. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |             |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| IB/0006/G | This was an application for a group of variations. Update of the SmPC following the assessment of the same changes for the reference product, Taxotere. Sections 4.4 and 4.8 of the SmPC are updated in order to add a warning related to respiratory disorders and to include interstitial pneumonitis, interstitial lung disease and pulmonary fibrosis as new adverse reactions observed the post-marketing setting following a relevant cumulative review of the originator product's safety database. The Package Leaflet is updated accordingly. In addition, Annex II is being brought in line with QRD template version 8.3. Furthermore, minor linguistic and typographical errors were rectified for the German, Hungarian and Lithuanian annexes. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference | 17/10/2013 | 22/05/2014 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |                       |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|
| IB/0005 | Update of the SmPC following the assessment of the same changes for the reference product, Taxotere. Sections 4.4 and 4.8 of the SmPC are updated in order to add a warning related to respiratory disorders and to include interstitial pneumonitis, interstitial lung disease and pulmonary fibrosis as new adverse reactions observed the post-marketing setting following a relevant cumulative review of the originator product's safety database. The Package Leaflet is updated accordingly. In addition, Annex II is being brought in line with QRD template version 8.3. Furthermore, minor linguistic and typographical errors were rectified for the German, Hungarian and Lithuanian annexes. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH | 29/05/2013 | 22/05/2014 | SmPC, Annex II and PL |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0001/G   | This was an application for a group of variations.   | 15/11/2012   | 15/11/2012   |
|-------------|------------------------------------------------------|--------------|--------------|

<div style=\"page-break-after: always\"></div>

|         | an obsolete parameter)                                                                                                                                                                                                                                                                                                                                        |            |            |                                  |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|
| II/0002 | Addition of pack size of 20 mg/1 ml to Docetaxel Kabi 20 mg/ml Concentrate for Solution for Infusion. B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, and biological/immunological multidose parenteral medicinal products | 20/09/2012 | 29/10/2012 | SmPC, Annex II, Labelling and PL |